Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE

Xavier Armoiry* (Corresponding Author), Hans-Martin Späth, Anna-Maria Henaine , Claude Dussart, Carl Counsell, Martin Connock

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds